📰 #Media – We’re pleased to share that the real‑world CHRONOS study, the largest evaluation to date of third‑line therapy in GI-aGVHD, has just been featured in CancerNetwork.
👉 Read the article here: www.cancernetwork.com/view/third-l...
#Microbiome #Microbiotherapy #aGvHD #Hematology #Oncology
📰 #PressRelease – MaaT Pharma announces publication of retrospective data from CHRONOS, a large real-world third-line GI-aGvHD study (n=59), in Bone Marrow Transplantation Journal.
🔗 Read the full press release: www.maatpharma.com/april-1st-20...
#Biotech #Hematology #aGvHD #GvHD #Microbiome
📰 #Media – Proud to be featured in Targeted Oncology highlighting the final Phase 3 ARES results of MaaT013, presented yesterday at EBMT by Prof. Florent Malard.
👉 Read the full article: www.targetedonc.com/view/microbi...
@theebmt.bsky.social
#Microbiome #Microbiotherapy #aGvHD #Hematology
Meredith shares her 25‑year journey living with chronic GvHD, the evolution of support resources, and how organizations like the #GVHDAlliance are pushing the field forward.
🎙️ Recorded LIVE from our booth at #Tandem26
#aGVHD #TransplantRadio
🔊 Listen to this exclusive interview with Dr. James L.M. Ferrara (Icahn School of Medicine at Mount Sinai) on Transplant Radio™ in booth 511 at #Tandem26!
🎧 Listen Now: lnkd.in/gESGm4R8
#agvhd #Tandem2026 #TransplantRADIO
What a great honor for Dr. James Ferrara at #Tandem26!
🎥 We recently recorded a four‑part video series highlighting his latest work.
Discover how MAGIC biomarkers and MAP scores can transform treatment decisions for steroid-resistant aGvHD.
💻 WATCH: www.linkedin.com/newsletters/...
#aGVHD #BMT
📢 [EVENT] – Join Guilhaume Deboras, Head of Corporate Development of MaaT Pharma, at the 10th Annual @Microbiome Movement Summit Europe, taking place on January 28-29 in London, UK.
👉 Learn more: microbiome-europe.com
#Microbiome #aGvHD #Oncology #Hematology #Innovation #Xervyteg
📰 MaaT Pharma featured in PharmaBoardroom!
Hervé Affagard, CEO and Co-Founder of MaaT Pharma, discusses the Company’s journey, scientific vision and path toward a potential first approval.
👉 Read the full interview here: pharmaboardroom.com/interviews/h...
#aGvHD #Oncology #Hematology #Microbiome
Cynata Therapeutics Completes Patient Enrollment in Clinical Trial for aGvHD Treatment #Australia #Melbourne #Cynata_Therapeutics #CYP-001 #aGvHD
📰 [Press Release] - Live from ASH 2025: MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
Read the full press release here: www.maatpharma.com/december-8-2...
#ASH2025 #aGvHD #Cancer
La NMPA de China otorga la aprobación condicional para la inyección de remestemcel-L-rknd
📩 info@dengyuemed.com
🔗https://dengyuepharma.com
#Ryoncil #remestemcelLrknd #aGVHD #GraftVersusHostDisease #StemCellTherapy #NMPA #DrugApproval #CellTherapy #Biotech #Hematology
Contact your Account Executive or Sign up:
forms.office.com/Pages/Respon...
#ASH2025 #Oncology #aGVHD #GVHD #IDsky #MedSKY #OncSKY
🩸 To close #BloodCancerAwarenessMonth, we share a patient story on life-threatening #aGvHD after transplant, featured by Bloomberg with Dr. Loschi’s insights.
🎥 Watch the full story: youtu.be/P8pd0TlITpo?...
At MaaT Pharma, we advance microbiome science to tackle unmet needs in hemato-oncology.
📄 [Press release] - MaaT Pharma Publishes its Half Year 2025 Financial Results and Provides a Business Update
👉 Read the full press release for more information: www.maatpharma.com/september-17...
#BusinessUpdate #FinancialResults #Oncology #Microbiome #aGvHD #Hematology
Scientists identified a donor-derived PD-1⁺CD8⁺ TSCM-like regulatory subset that alleviates #aGvHD, preserves GVL, supports immune reconstitution, offering #biomarkers for donor selection & potential cell therapy in #alloHSCT.
#STTT #OpenAccess: doi.org/10.1038/s413...
📄 [Press release] – MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025.
👉 For more information, read the full press release: www.maatpharma.com/june-19-2025...
#BloodCancers #Cancer #aGvHD #Microbiome #MAA #EMA #Oncology #GeneralMeeting #Xervyteg #Business
🎥 Eric Soyer, CFO of MaaT Pharma, shares insights in an interview with La Bourse et la Vie TV about the key highlights of this year’s first quarter.
👉 Watch the full interview conducted by Didier Testot: www.labourseetlavie.com/strategies/p...
#Investors #aGvHD #Immunology #Oncology #Microbiome
📄 [EHA2025] – MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress.
👉 Read the press release: www.maatpharma.com/may-14-2025-...
#EHA #EAP #Phase3 #aGvHD #alloHSCT #Microbiome #Oncology #Cancer #Hematology
📄 [Press release] – MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025.
If you’d like to know more, please read the press release: www.maatpharma.com/may-13-2025-...
#BloodCancers #Cancer #aGvHD #Safety #Microbiome #FinancialResults #MAA #Oncology
🧪 It's Lab Week 2025! | DAY 1
We’re solving cases from pre- & post-transplant testing to rare infections & immune conditions.
First up is our aGVHD Algorithms.
🥼 aGVHD: www.eurofins-viracor.com/our-testing/...
#LabWeek2025 #aGVHD #MysteryMachineofDiagnostics #LabLife #CelebrateLabWeek
📢 [Press Release] - MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results
If you’d like to know more, please read the press release: www.maatpharma.com/032725-maat-...
#BloodCancers #aGvHD #Milestone #Microbiome #FinancialResults
📄[Press release] – MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013 for the treatment of acute Graft-versus-Host Disease🩸
See the press release: maatpharma.com/march-11-202...
#Cancer #EMA #aGvHD #Pediatric #EMA #Milestone
📅 [Event] – Thrilled to share that Gianfranco Pittari, MD PhD, CMO at MaaT Pharma, will present the Positive Phase 3 data for our lead asset MaaT013 in treating #aGvHD at the Microbiome Times Partnering Forum, organized by The Microbiome Times and in collaboration with MTIG and EMIH.
Today is the 3nd annual #GVHDday. This Day was established to symbolize an enduring solidarity with the GVHD community.
Help amplify the voices affected by GVHD & share this message.
🌐 Visit GVHDalliance.org to get involved.
#GVHDconnect4hope #GVHDAlliance #aGVHD #BMT #HSCT #HCT #bmtsm #Tandem25
This #GvHDday, we envision a tomorrow where people with #aGvHD have access to more treatment options and improved outcomes than are available today. This vision drives our work for #patients. Hear more from Professor Mohamed Mohty about why the need is so urgent.
🏖️ It’s Day 4 at the #TandemMeetings!
Say aloha at BOOTH# 500
🤝 Scientists of @eurofinsviracor.bsky.social
⭐ Let’s discuss our diagnostics!
🦴 aGVHD Diagnostics: www.eurofins-viracor.com/our-testing/...
🍄 NeXGen Fungal / AFB NGS: www.eurofins-viracor.com/our-testing/...
#aGVHD #Tandem25 #hawaii
🧪 NEW ASSAY!
Manhattan Plus MAGIC aGVHD Composite Risk Analysis Assay.
READ 👉 www.eurofins-viracor.com/test-menu/40...
Better stratification & analysis of symptomatic aGVHD risks with NEW Manhattan scoring algorithm inclusion.
• Improved prognostic performance(6mo non-relapse mortality) #agvhd #bmt
📰 – Proud to keep sharing the positive Phase 3 data in #aGvHD through media coverage, this time featured in Scrip, Citeline Commercial! Thanks to Alaric DeArment for reporting on our milestones, including the Phase 3 data and our EMA filing.
👉 Read the article: insights.citeline.com/scrip/therap...
💡 What does recent data tell us about the potential for targeting #aGvHD through the #microbiome? ICYMI, learn more about our Phase 3 results from Professor Mohamad Mohty:
📅 [EVENT] – Join Alexandre Kiss, Europe Medical Advisor for Oncology and Hematology at MaaT Pharma, at the 17th “Journée Greffe” of the Paoli-Calmettes Institute, on January 25, in Marseille, France.
A key moment to shape the future of #transplant programs!
#aGvHD #GvHD #BloodCancers #HSCT
